173 related articles for article (PubMed ID: 24942576)
1. HIV-1 and HIV-2 Vif interact with human APOBEC3 proteins using completely different determinants.
Smith JL; Izumi T; Borbet TC; Hagedorn AN; Pathak VK
J Virol; 2014 Sep; 88(17):9893-908. PubMed ID: 24942576
[TBL] [Abstract][Full Text] [Related]
2. APOBEC3 degradation is the primary function of HIV-1 Vif determining virion infectivity in the myeloid cell line THP-1.
Ikeda T; Shimizu R; Nasser H; Carpenter MA; Cheng AZ; Brown WL; Sauter D; Harris RS
mBio; 2023 Aug; 14(4):e0078223. PubMed ID: 37555667
[TBL] [Abstract][Full Text] [Related]
3. Functional analysis of Vif protein shows less restriction of human immunodeficiency virus type 2 by APOBEC3G.
Ribeiro AC; Maia e Silva A; Santa-Marta M; Pombo A; Moniz-Pereira J; Goncalves J; Barahona I
J Virol; 2005 Jan; 79(2):823-33. PubMed ID: 15613310
[TBL] [Abstract][Full Text] [Related]
4. Identification of two APOBEC3F splice variants displaying HIV-1 antiviral activity and contrasting sensitivity to Vif.
Lassen KG; Wissing S; Lobritz MA; Santiago M; Greene WC
J Biol Chem; 2010 Sep; 285(38):29326-35. PubMed ID: 20624919
[TBL] [Abstract][Full Text] [Related]
5. The structural basis for HIV-1 Vif antagonism of human APOBEC3G.
Li YL; Langley CA; Azumaya CM; Echeverria I; Chesarino NM; Emerman M; Cheng Y; Gross JD
Nature; 2023 Mar; 615(7953):728-733. PubMed ID: 36754086
[TBL] [Abstract][Full Text] [Related]
6. Multiple APOBEC3 restriction factors for HIV-1 and one Vif to rule them all.
Desimmie BA; Delviks-Frankenberrry KA; Burdick RC; Qi D; Izumi T; Pathak VK
J Mol Biol; 2014 Mar; 426(6):1220-45. PubMed ID: 24189052
[TBL] [Abstract][Full Text] [Related]
7. Maedi-visna virus Vif protein uses motifs distinct from HIV-1 Vif to bind zinc and the cofactor required for A3 degradation.
Knecht KM; Hu Y; Rubene D; Cook M; Ziegler SJ; Jónsson SR; Xiong Y
J Biol Chem; 2021; 296():100045. PubMed ID: 33465707
[TBL] [Abstract][Full Text] [Related]
8. Promiscuous RNA binding ensures effective encapsidation of APOBEC3 proteins by HIV-1.
Apolonia L; Schulz R; Curk T; Rocha P; Swanson CM; Schaller T; Ule J; Malim MH
PLoS Pathog; 2015 Jan; 11(1):e1004609. PubMed ID: 25590131
[TBL] [Abstract][Full Text] [Related]
9. Running loose or getting lost: how HIV-1 counters and capitalizes on APOBEC3-induced mutagenesis through its Vif protein.
Münk C; Jensen BE; Zielonka J; Häussinger D; Kamp C
Viruses; 2012 Nov; 4(11):3132-61. PubMed ID: 23202519
[TBL] [Abstract][Full Text] [Related]
10. A computational exploration of global and temporal dynamics of selection pressure on HIV-1 Vif polymorphism.
Arman MS; Hasan MZ
Virus Res; 2024 Mar; 341():199323. PubMed ID: 38237808
[TBL] [Abstract][Full Text] [Related]
11. Structural insights into RNA bridging between HIV-1 Vif and antiviral factor APOBEC3G.
Kouno T; Shibata S; Shigematsu M; Hyun J; Kim TG; Matsuo H; Wolf M
Nat Commun; 2023 Jul; 14(1):4037. PubMed ID: 37419875
[TBL] [Abstract][Full Text] [Related]
12. Design of Vif-Derived Peptide Inhibitors with Anti-HIV-1 Activity by Interrupting Vif-CBFβ Interaction.
Gai Y; Duan S; Wang S; Liu K; Yu X; Yang C; Li G; Zhou Y; Yu B; Wu J; Wang C; Yu X
Viruses; 2024 Mar; 16(4):. PubMed ID: 38675833
[TBL] [Abstract][Full Text] [Related]
13. APOBEC3 multimerization correlates with HIV-1 packaging and restriction activity in living cells.
Li J; Chen Y; Li M; Carpenter MA; McDougle RM; Luengas EM; Macdonald PJ; Harris RS; Mueller JD
J Mol Biol; 2014 Mar; 426(6):1296-307. PubMed ID: 24361275
[TBL] [Abstract][Full Text] [Related]
14. Mapping the Vif-A3G interaction using peptide arrays: a basis for anti-HIV lead peptides.
Reingewertz TH; Britan-Rosich E; Rotem-Bamberger S; Viard M; Jacobs A; Miller A; Lee JY; Hwang J; Blumenthal R; Kotler M; Friedler A
Bioorg Med Chem; 2013 Jun; 21(12):3523-32. PubMed ID: 23545135
[TBL] [Abstract][Full Text] [Related]
15. Direct inhibition of human APOBEC3 deaminases by HIV-1 Vif independent of the proteolysis pathway.
Kamba K; Wan L; Unzai S; Morishita R; Takaori-Kondo A; Nagata T; Katahira M
Biophys J; 2024 Feb; 123(3):294-306. PubMed ID: 38115583
[TBL] [Abstract][Full Text] [Related]
16. Flexibility in Nucleic Acid Binding Is Central to APOBEC3H Antiviral Activity.
Bohn JA; DaSilva J; Kharytonchyk S; Mercedes M; Vosters J; Telesnitsky A; Hatziioannou T; Smith JL
J Virol; 2019 Dec; 93(24):. PubMed ID: 31578294
[TBL] [Abstract][Full Text] [Related]
17. Structural basis of HIV-1 Vif-mediated E3 ligase targeting of host APOBEC3H.
Ito F; Alvarez-Cabrera AL; Kim K; Zhou ZH; Chen XS
Nat Commun; 2023 Aug; 14(1):5241. PubMed ID: 37640699
[TBL] [Abstract][Full Text] [Related]
18. On the solution conformation and dynamics of the HIV-1 viral infectivity factor.
Marcsisin SR; Narute PS; Emert-Sedlak LA; Kloczewiak M; Smithgall TE; Engen JR
J Mol Biol; 2011 Jul; 410(5):1008-22. PubMed ID: 21763503
[TBL] [Abstract][Full Text] [Related]
19. High-speed atomic force microscopy directly visualizes conformational dynamics of the HIV Vif protein in complex with three host proteins.
Pan Y; Shlyakhtenko LS; Lyubchenko YL
J Biol Chem; 2020 Aug; 295(34):11995-12001. PubMed ID: 32587092
[TBL] [Abstract][Full Text] [Related]
20. Evolutionary Conservation of PP2A Antagonism and G2/M Cell Cycle Arrest in Maedi-Visna Virus Vif.
Luperchio AM; Jónsson SR; Salamango DJ
Viruses; 2022 Aug; 14(8):. PubMed ID: 36016323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
